Enterococcus faecium and VRE Infection Models

Enterococcus faecium (E. faecium) has followed one of the more troubling trajectories in clinical microbiology, changing from an ordinary gut commensal into one of the most treatment-resistant pathogens in the modern hospital. Its infections span a wide clinical range, from asymptomatic gut colonization to invasive, systemic disease, and an antimicrobial candidate may be developed as a gut-targeted or a systemic therapy. TransPharm Preclinical Solutions’s validated in vivo models cover that range and can produce the quantitative efficacy data a development program needs.

E. faecium is a Gram-positive coccus and a normal commensal of the gastrointestinal tract. Given the opportunity (a disrupted microbiota, a vulnerable host, an indwelling device, etc.) it becomes an opportunistic pathogen, causing bloodstream, intra-abdominal, urinary, and wound infections, predominantly in hospitalized and immunocompromised patients. It is a capable biofilm former and persists readily in the healthcare environment.

As one of the six ESKAPE pathogens, E. faecium is defined clinically by its resistance. It is the more drug-resistant of the two major enterococcal species, with widespread high-level ampicillin resistance and, in many strains, acquired vancomycin resistance (also known as vancomycin-resistant enterococci or VRE). That resistance profile – and its shrinking set of treatment options– is what makes robust, reproducible preclinical models essential to developing the next generation of anti-enterococcal therapies.

E. faecium is difficult to model well because it causes two distinct kinds of infection – persistent gastrointestinal colonization and invasive infection of normally sterile sites such as the bloodstream and peritoneum – and a given candidate is usually only intended to treat one or the other. The design of a meaningful efficacy study therefore depends on matching the model to the target indication and the challenge strain to the relevant resistance profile. Enterococci are intrinsically resistant to several antibiotic classes, including cephalosporins and clinically achievable concentrations of aminoglycosides, and E. faecium frequently acquires additional resistance through mobile genetic elements, so strain selection is as important as model selection.

TransPharm Preclinical Solutions’s two validated E. faecium models correspond to these two infection types. The gastrointestinal model reproduces gut colonization – the setting in which enterococci, including VRE, establish and persist – and is the appropriate context for evaluating decolonization and gut-targeted therapies. The peritonitis model reproduces invasive intra-abdominal infection, with survival and organ/blood bacterial burden as endpoints. A sponsor can run a colonization study, a systemic-infection study, or both.

TransPharm Preclinical Solutions has validated E. faecium studies using strain 03B1022 in both models. TransPharm Preclinical Solutions also maintains an on-site library of hundreds of validated pathogens, including many multidrug-resistant strains. Additional strains, including sponsor-supplied isolates or characterized resistant clinical isolates, can be sourced and validated to a program’s specifications upon request.

Because an E. faecium program can target colonization or invasive disease, the starting point is matching model, strain, and readout to that intent; from there, challenge strain, route of administration, comparator agents, and dosing schedule can all be individually configured. The core readouts are quantitative bacterial burden (CFU) in feces, target tissues, organs, and blood, together with survival and clinical monitoring, where applicable.

The following are available as add-ons to any study:

• Pharmacokinetic profiling and PK/PD analysis
• Blood chemistry
• Additional tissue harvests
• Histopathology

Mice are challenged with E. faecium by oral gavage, typically after a cocktail of antibiotics in the drinking water disrupts their native microbiota and increases susceptibility to colonization – the same loss of colonization resistance that predisposes patients to enterococcal overgrowth. Test article can be delivered by oral (PO) or perirectal (PR) routes, by subcutaneous (SC), intravenous (IV), or intraperitoneal (IP) injection, or via diet or drinking water. Endpoints include fecal CFU burden tracked over time, body weight, clinical observations, and mortality, with CFU in organs and blood available. This design is well suited to colonization and decolonization studies. Validated in mice.

For E. faecium, the peritonitis model represents invasive enterococcal disease: the intra-abdominal and bloodstream infection that follows when the organism escapes the gut. Animals are challenged by intraperitoneal injection, with gastric mucin used to help establish infection where needed. Endpoints include survival (mortality tracking) and CFU burden in harvested organs and blood, supporting both lethality- and burden-based efficacy readouts. Validated in mice and rats.

In vitro work complements the in vivo models and is often where an E. faecium program starts. TransPharm Preclinical Solutions runs MIC testing by agar and broth dilution per CLSI, along with MBC, time-kill kinetics, and checkerboard analysis/synergy testing. Checkerboard analysis is particularly relevant for resistant enterococci, where combination regimens are frequently required.

Vancomycin-resistant enterococci (VRE) are a leading cause of resistant healthcare-associated infection and a WHO priority pathogen, with E. faecium being the predominant species. Resistance arises when the organism acquires a van gene cluster (most commonly vanA or vanB) that remodels the cell-wall building block, replacing its terminal D-alanyl-D-alanine with D-alanyl-D-lactate. Vancomycin binds this altered target with roughly a thousandfold lower affinity, so it can no longer block cell-wall synthesis. vanA confers high-level resistance to both vancomycin and teicoplanin; vanB typically affects vancomycin alone. Layered on top of the intrinsic resistance already characteristic of enterococci, this leaves very few reliable treatment options and drives the need for new therapies.

Because VRE is fundamentally E. faecium with an added resistance determinant, it is evaluated in the same two models, with the resistant isolate as the challenge strain. Characterized VRE isolates can be sourced and validated to your program’s specifications, and client-supplied resistant strains are welcome. In vitro susceptibility and checkerboard analysis further support evaluation of single agents and combination regimens against resistant enterococci.